Megestrol (INN, BAN) is a progestin of the 17α-hydroxyprogesterone group which was, until recently, never marketed or used clinically.[1][2] It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer.[3] Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.[1][2]
Medical Use
As of June 2023, megestrol is being used to treat significant weight loss in HIV/AIDS patients, and as a palliative treatment of endometrial and breast cancers. It can be administered in both tablet and oral suspension forms, with dosages ranging from 100 mg/day to 1600 mg/day depending on the condition being treated.[3]
Synthesis
See also
References
- ^ a b Macdonald F (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1267. ISBN 978-0-412-46630-4. Retrieved 12 May 2012.
- ^ a b Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 641. ISBN 978-3-88763-075-1. Retrieved 28 May 2012.
- ^ a b Manikkuttiyil C, Nguyen H (2024). "Megestrol". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32644631. Retrieved 2024-04-25.
- ^ Ringold HJ, Ruelas JP, Batres E, Djerassi C (1959). "Steroids. CXVIII.16-Methyl Derivatives of 17α-Hydroxyprogesterone and of Reichstein's Substance "S"". Journal of the American Chemical Society. 81 (14): 3712–3716. Bibcode:1959JAChS..81.3712R. doi:10.1021/ja01523a055.